SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Soros Fund Management LLC, et al. – ‘SC 13D/A’ on 3/13/97 re: Pharmacyclics Inc – EX-99.F

As of:  Thursday, 3/13/97   ·   Accession #:  921530-97-58   ·   File #:  5-46749

Previous ‘SC 13D’:  ‘SC 13D’ on 3/13/97   ·   Next:  ‘SC 13D/A’ on 3/27/97   ·   Latest:  ‘SC 13D/A’ on 8/6/14

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/13/97  Soros Fund Management LLC         SC 13D/A               3:29K  Pharmacyclics Inc                 Akin Gump Strauss H… LLP
          George Soros
          QIH Management Investor, L.P.
          QIH Management, Inc.
          Quantum Industrial Partners Ldc
          Soros Fund Management LLC
          Stanley F. Druckenmiller

Amendment to General Statement of Beneficial Ownership   —   Schedule 13D
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC 13D/A    Amend No. 1 to 13D Re Pharmacyclics, Inc.             15     46K 
 2: EX-99.C     Exhibit C - Joint Filing Agreement                     1      6K 
 3: EX-99.F     Exhibit F - Assignment and Transfer Agreemen           3     12K 


EX-99.F   —   Exhibit F – Assignment and Transfer Agreemen

EX-99.F1st Page of 3TOCTopPreviousNextBottomJust 1st
 

Page 17 of 19 Pages EXHIBIT F ASSIGNMENT AND TRANSFER AGREEMENT ASSIGNMENT AND TRANSFER AGREEMENT (the "Agreement"), dated as of March 11, 1997, by and between Quantum Industrial Partners LDC ("QIP"), a Cayman Islands limited duration company, and Quantum Partners LDC ("Quantum Partners"), a Cayman Islands limited duration company. WHEREAS, on February 21, 1997 (the "Closing Date"), QIP entered into a Common Stock Purchase Agreement (the "Purchase Agreement") with Pharmacyclics, Inc. ("Pharmacyclics") pursuant to which QIP purchased 600,000 shares of common stock, par value $.0001 (the "Shares"), of Pharmacyclics for an aggregate amount of $11,430,000; WHEREAS, QIP wishes to assign and transfer the Shares to Quantum Partners and to assign and transfer its rights and obligations under the Purchase Agreement to Quantum Partners, and Quantum Partners wishes to accept such assignment and transfer and replace and novate QIP as a party to the Purchase Agreement. NOW THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 1. Assignment and Transfer. (a) QIP hereby assigns and -------------------------- transfers to Quantum Partners as of the Closing Date, free and clear of all liens, mortgages, pledges, security interests or other encumbrances of any kind, its entire right, title and interest to and in the Shares, which are fully paid and non-assessable, and Quantum Partners, as of the Closing Date, shall be deemed the owner of the Shares for all purposes. In consideration of the aforesaid assignment and transfer, Quantum Partners is remitting to QIP concurrently herewith $11,430,000 as the purchase price of the Shares. (b) Quantum Partners hereby accepts the assignment and transfer referred to in Section 1(a) hereof. In consideration of such acceptance and the payment by Quantum Partners to QIP referred to in Section 1(a), QIP is delivering the Shares to Quantum Partners concurrently herewith. 2. Novation and Substitution. (a) Effective as of the Closing -------------------------- Date, Quantum Partners shall be replaced, novated and, for all purposes, substituted for QIP as a party to the Purchase Agreement. 1
EX-99.F2nd Page of 3TOC1stPreviousNextBottomJust 2nd
Page 18 of 19 Pages (b) Effective as of the Closing Date, (i) the representations, warranties and covenants given by QIP shall be deemed to have been given by Quantum Partners and Quantum Partners makes and reaffirms such representations, warranties and covenants to and for the benefit of Pharmacyclics, (ii) Quantum Partners shall be entitled to all the rights and privileges of the Purchase Agreement accruing to QIP, and (iii) QIP shall be released and discharged from all liabilities and obligations with respect to the Purchase Agreement. 3. Agreement Binding and to Benefit Assignees. Each party ---------------------------------------------- hereto represents that this Agreement has been duly authorized, executed and delivered by it and is valid, binding and enforceable against it, and this Agreement shall inure to the benefit of the parties hereto and their successors and assigns. 4. Governing Law. This Agreement shall be construed and -------------- enforced in all respects according to the internal laws of the State of New York applicable to agreements executed and performed therein without giving effect to any choice of law rules thereof that may direct the application of the laws of another jurisdiction. 5. Counterparts. This Agreement may be executed in several ------------ counterparts, each of which shall be deemed an original but all of which shall constitute one and the same instrument. 2
EX-99.FLast Page of 3TOC1stPreviousNextBottomJust 3rd
Page 19 of 19 Pages IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly authorized officers or agents of the parties hereof as of the date set forth above. QUANTUM INDUSTRIAL PARTNERS LDC By: /S/ MICHAEL C. NEUS ---------------------------------- Michael Neus Attorney-in-Fact QUANTUM PARTNERS LDC By: /S/ MICHAEL C. NEUS ---------------------------------- Michael C. Neus Attorney-in-Fact Pharmacyclics hereby acknowledges and agrees to the terms of this Agreement, specifically the novation of QIP and the substitution of Quantum Partners as party to the Purchase Agreement. PHARMACYCLICS, INC. By: /S/ CHERYL JASZEWSKI ---------------------------------- Name: Cheryl Jaszewski Title: Vice President 3

Dates Referenced Herein   and   Documents Incorporated by Reference

Referenced-On Page
This ‘SC 13D/A’ Filing    Date First  Last      Other Filings
Filed on:3/13/97SC 13D
3/11/971
2/21/971
 List all Filings 
Top
Filing Submission 0000921530-97-000058   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Apr. 26, 7:36:56.1pm ET